Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Drops By 18.4%

Vigil Neuroscience, Inc. (NASDAQ:VIGL) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 681,400 shares, a decrease of 18.4% from the November 30th total of 835,500 shares. Currently, 3.5% of the shares of the stock are short sold. Based on an average trading volume of 190,300 shares, the days-to-cover ratio is presently 3.6 days.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC acquired a new stake in Vigil Neuroscience during the 2nd quarter valued at $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vigil Neuroscience during the second quarter valued at $87,000. Renaissance Technologies LLC increased its position in Vigil Neuroscience by 19.2% during the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after purchasing an additional 11,536 shares in the last quarter. Walleye Capital LLC raised its stake in Vigil Neuroscience by 334.4% in the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after purchasing an additional 92,217 shares during the last quarter. Finally, Verition Fund Management LLC purchased a new position in Vigil Neuroscience in the 3rd quarter valued at about $442,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Vigil Neuroscience Trading Down 7.3 %

Shares of VIGL opened at $1.53 on Tuesday. Vigil Neuroscience has a 12-month low of $1.49 and a 12-month high of $6.06. The stock has a market cap of $62.54 million, a P/E ratio of -0.74 and a beta of 1.65. The company has a 50-day moving average of $2.75 and a two-hundred day moving average of $3.38.

Analyst Ratings Changes

Several brokerages have commented on VIGL. JMP Securities restated a “market outperform” rating and set a $22.00 target price on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. William Blair initiated coverage on shares of Vigil Neuroscience in a research report on Wednesday, December 4th. They set an “outperform” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $17.00 price target on shares of Vigil Neuroscience in a research report on Friday, November 8th. Finally, Wedbush boosted their price target on Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $19.75.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.